Increasingly, pharma and biotech companies are looking towards personalized medicine to guide their portfolios, developing therapies designed to address the needs of individual patient populations.
Nanobiotix (EMA:NANO) has chosen to look in the other direction, according to co-founder & CEO Laurent Levy.
“What we have done in our company is trying to go for the opposite: to find 1 product that could potentially help millions of patients,” Levy told Drug Delivery Business News.
Get the full story at our sister site, Drug Delivery Business News.